AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
This piece explains withdrawal rate concepts for index fund retirement planning, outlining how to set sustainable rates and monitor portfolio health.
22,391 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Choosing a short-term bond ETF can feel tricky. This guide compares IGSB and VGSH on cost, yield, risk, and portfolio...
Oxford Square Capital trades at a 24% yield, yet a steep NAV decline and Q4 losses cast doubt on earnings durability....
Bank earnings just dropped fresh clues about how Americans are spending, borrowing, and saving. This deep dive breaks...
When private materials move from a safe shelf to a digital vault, money and privacy collide. This article examines hu...
A public figure’s family offers a million-dollar incentive to help locate a missing loved one. This article breaks do...
Silicon Valley legend Vinod Khosla says he will remain in California despite a sweeping wealth tax proposal, urging l...
A last-minute cancellation can hit wallets as hard as plans. This guide breaks down how to navigate refunds, recover ...
Public feuds grab headlines and dollars alike. This article uses the Katie Price reignites Victoria moment to show pr...
A high-profile trademark dispute around the 1587 Prime restaurant tests more than litigation—it tests how branding, c...
A cybersecurity-focused ETF bearing the infamous ticker SPAM is delivering strong 2026 gains, tripling the S&P 500's ...
Berkshire Hathaway's Greg Abel could be quietly steering a strategic tilt toward AI-enabled winners. This deep dive e...